Neuroprotective and restorative effects of intrastriatal grafting of encapsulated GDNF‐producing cells in a rat model of Parkinson's disease

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Journal of Neuroscience Research

• Publication date

  2002-09-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/jnr.10375PMID 12205688
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Enhancement of survival of stored dopaminergic cells and promotion of graft survival by exposure of human fetal nigral tissue to glial cell line--derived neurotrophic factor in patients with Parkinson's disease. Report of two cases and technical considerations.

  2000cited by this paper
• Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease.

  2000cited by this paper
• Long-Term rAAV-Mediated Gene Transfer of GDNF in the Rat Parkinson's Model: Intrastriatal But Not Intranigral Transduction Promotes Functional Regeneration in the Lesioned Nigrostriatal System

  2000influential reference
• Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice.

  1999cited by this paper
• Clinicopathological findings following intraventricular glial‐derived neurotrophic factor treatment in a patient with Parkinson's disease

  1999cited by this paper
• [Neurturin: a relative of glial-cell-line-derived neurotrophic factor].

  1998cited by this paper
• Long‐term protection of the rat nigrostriatal dopaminergic system by glial cell line‐derived neurotrophic factor against 6‐hydroxydopamine in vivo

  1998cited by this paper
• Glial cell line-derived neurotrophic factor improves intrastriatal graft survival of stored dopaminergic cells

  1998cited by this paper
• Long-term enhanced chromaffin cell survival and behavioral recovery in hemiparkinsonian rats with co-grafted polymer-encapsulated human NGF-secreting cells.

  1997cited by this paper
• Dopaminergic Neurons Protected from Degeneration by GDNF Gene Therapy

  1997cited by this paper
• Studies on neuroprotective and regenerative effects of GDNF in a partial lesion model of Parkinson's disease.

  1997cited by this paper
• GDNF Protection against 6-OHDA: Time Dependence and Requirement for Protein Synthesis

  1997cited by this paper
• GDNF Reduces Drug-Induced Rotational Behavior after Medial Forebrain Bundle Transection by a Mechanism Not Involving Striatal Dopamine

  1997cited by this paper
• Intrastriatal glial cell line-derived neurotrophic factor promotes sprouting of spared nigrostriatal dopaminergic afferents and induces recovery of function in a rat model of Parkinson's disease.

  1997cited by this paper
• Neurturin, a relative of glial-cell-line-derived neurotrophic factor

  1996cited by this paper
• Glial Cell Line‐derived Neurotrophic Factor: the Lateral Cerebral Ventricle as a Site of Administration for Stimulation of the Substantia Nigra Dopamine System in Rats

  1996cited by this paper
• Short-Term GDNF Treatment Provides Long-Term Rescue of Lesioned Nigral Dopaminergic Neurons in a Rat Model of Parkinson’s Disease

  1996cited by this paper
• Intranigral or intrastriatal injections of GDNF: effects on monoamine levels and behavior in rats.

  1996cited by this paper
• Alleviation of behavioral deficits in aged rodents following implantation of encapsulated GDNF-producing fibroblasts.

  1996cited by this paper
• Intrastriatal injection of GDNF attenuates the effects of 6‐hydroxydopamine

  1996cited by this paper
• GDNF protects against 6-OHDA nigrostriatal lesion: in vivo study with microdialysis and PET

  1995cited by this paper
• GDNF prevents degeneration and promotes the phenotype of brain noradrenergic neurons in vivo.

  1995cited by this paper
• Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease.

  1995cited by this paper
• Glial cell line-derived neurotrophic factor but not transforming growth factor beta 3 prevents delayed degeneration of nigral dopaminergic neurons following striatal 6-hydroxydopamine lesion.

  1995cited by this paper
• GDNF protects nigral dopamine neurons against 6-hydroxydopamine in vivo.

  1995cited by this paper
• GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons.

  1993cited by this paper
• Ciliary neurotrophic factor prevents degeneration of adult rat substantia nigra dopaminergic neurons in vivo.

  1993cited by this paper
• Brain-derived neurotrophic factor augments rotational behavior and nigrostriatal dopamine turnover in vivo.

  1992cited by this paper
• Epidermal Growth Factor Enhances Striatal Dopaminergic Parameters in the 1‐Methyl‐4‐Phenyl‐l, 2, 3, 6‐Tetrahydropyridine‐Treated Mouse

  1991cited by this paper
• Efficient selection for high-expression transfectants with a novel eukaryotic vector

  1991cited by this paper
• Efficient selection for high-expression transfectants with a novel eukaryotic vector.

  1991cited by this paper
• MPTP-treated young mice but not aging mice show partial recovery of the nigrostriatal dopaminergic system by stereotaxic injection of acidic fibroblast growth factor (aFGF).

  1990cited by this paper
• Basic FGF reverses chemical and morphological deficits in the nigrostriatal system of MPTP-treated mice

  1990cited by this paper
• The rat brain in stereotaxic coordinates: Authors: George Paxinos & Charles Watson Academic Press Australia, 1982 Softback, 154 pages (including 71 plates), 35.00 Aust $

  1983cited by this paper

• Synthetic microneurotrophins: Neurotrophin receptors for therapeutics of neurodegenerative diseases

  2025cites this paper
• Neurotrophic factors hold promise for the future of Parkinson’s disease treatment: is there a light at the end of the tunnel?

  2018cites this paper
• Title The potential of neurotrophic factors for the treatment of Parkinson ' s disease

  2018cites this paper
• Dendritic processes as targets for arsenic induced neurotoxicity: Protective role of curcumin

  2018cites this paper
• Differential responses of Trans-Resveratrol on proliferation of neural progenitor cells and aged rat hippocampal neurogenesis

  2016cites this paper
• Gene therapy for neurological disorders

  2016cites this paper
• Molecular Mechanism of Switching of TrkA/p75NTR Signaling in Monocrotophos Induced Neurotoxicity

  2015cites this paper
• Carriers in Cell-Based Therapies for Neurological Disorders

  2014cites this paper
• The characterization of hyaluronic acid and polyethylene glycol hydrogels for neural tissue engineering

  2014cites this paper
• La vitamina D regula la expresión del factor neurotrófico GDNF en cultivos neuronales estriatales y en ratas normales y hemiparkinsonianas

  2014cites this paper
• Encapsulated cell therapy for neurodegenerative diseases: from promise to product.

  2014cites this paper
• Zirconium oxide ceramic foam: a promising supporting biomaterial for massive production of glial cell line-derived neurotrophic factor

  2014cites this paper
• Neurotrophic and neuroprotective efficacy of intranasal GDNF in a rat model of Parkinson's disease.

  2014cites this paper
• In vivo administration of VEGF- and GDNF-releasing biodegradable polymeric microspheres in a severe lesion model of Parkinson's disease.

  2013cites this paper
• Hypoxic-Ischemic Neonatal Encephalopathy: Animal Experiments for Neuroprotective Therapies

  2013cites this paper
• Motor complications in Parkinson's disease: a comprehensive review of emergent management strategies.

  2013cites this paper
• Cholinergic Dysfunctions and Enhanced Oxidative Stress in the Neurobehavioral Toxicity of Lambda-Cyhalothrin in Developing Rats

  2012influential citation
• A perspective on bioactive cell microencapsulation.

  2012cites this paper
• Chronic clomipramine treatment restores hippocampal expression of glial cell line-derived neurotrophic factor in a rat model of depression.

  2012cites this paper
• Stem Cells for Neurodegenerative Disorders

  2012cites this paper
• Neurotrophic factors and neurodegenerative diseases: a delivery issue.

  2012cites this paper
• Involvement of dopaminergic and serotonergic systems in the neurobehavioral toxicity of lambda-cyhalothrin in developing rats.

  2012cites this paper
• Encapsulated cell-based biodelivery of Meteorin is neuroprotective in the quinolinic acid rat model of neurodegenerative disease

  2012cites this paper
• Expressão de GDNF em células estriatais: efeito de fatores solúveis libertados por células do mesencéfalo ventral após lesão dopaminérgica

  2012cites this paper
• Neurodegenerative Shielding by Curcumin and Its Derivatives on Brain Lesions Induced by 6-OHDA Model of Parkinson's Disease in Albino Wistar Rats

  2012cites this paper
• A Perspective on Bioactive Cell Microencapsulation

  2012cites this paper
• Potential of Pluripotent Stem Cells for the Replacement of Inner Ears

  2011cites this paper
• The effect of lentivirus-mediated TH and GDNF genetic engineering mesenchymal stem cells on Parkinson’s disease rat model

  2011cites this paper
• Neuroprotective efficacy of curcumin in arsenic induced cholinergic dysfunctions in rats.

  2011cites this paper
• Neurotrophic factors for the treatment of Parkinson's disease.

  2011cites this paper
• Kerttu Koskenniemi Proteomic Characterization of Probiotic Lactobacillus rhamnosus GG 3 / 2012 Laura Lahti FGF Signaling in Neurogenesis and Patterning of the Developing Midbrain and Anterior Hindbrain

  2011cites this paper
• Neuroprotective and anti-stress effect of A68930 in acute and chronic unpredictable stress model in rats.

  2011cites this paper
• Cytoprotective effects of growth factors: BDNF more potent than GDNF in an organotypic culture model of Parkinson's disease.

  2011cites this paper
• The potential of neurotrophic factors for the treatment of Parkinson's disease

  2011cites this paper
• The Role of Oxygen During In Vitro Culture and Immunoisolation of Islets of Langerhans

  2011cites this paper
• Use of growth factors for the treatment of Parkinson’s disease

  2010cites this paper
• [Cell encapsulation for the treatment of central nervous system disorders].

  2010cites this paper
• Gene therapy for Parkinson's disease.

  2009cites this paper
• Some observations on the tropism of Japanese encephalitis virus in rat brain.

  2009cites this paper
• Enhanced survival and function of neural stem cells‐derived dopaminergic neurons under influence of olfactory ensheathing cells in parkinsonian rats

  2009cites this paper
• Attenuation of arsenic neurotoxicity by curcumin in rats.

  2009cites this paper
• Neurological disorders and neural regeneration, with special reference to Parkinson’s disease and cerebral ischemia

  2009cites this paper
• Artificial organs: recent progress in artificial hearing and vision

  2009cites this paper
• Neurotransmitter and Neurotrophic Factor-Secreting Cell Line Grafting for the Treatment of Parkinson’s Disease

  2008cites this paper
• Comparison of the therapeutic potential of adult and embryonic neural precursor cells in a rat model of Parkinson disease.

  2008cites this paper
• Encapsulated cell biodelivery of GDNF: a novel clinical strategy for neuroprotection and neuroregeneration in Parkinson's disease?

  2008cites this paper
• Potential cellular and regenerative approaches for the treatment of Parkinson’s disease

  2008cites this paper
• Zuckerkandl's organ improves long-term survival and function of neural stem cell derived dopaminergic neurons in Parkinsonian rats.

  2008cites this paper
• Human umbilical cord blood-derived CD34+ cells can be used as a prophylactic agent for experimental heatstroke.

  2008cites this paper
• Multiple Molecular Pathways Are Involved in the Neuroprotection of GDNF Against Proteasome Inhibitor Induced Dopamine Neuron Degeneration In Vivo

  2008cites this paper
• Role of PI3-K/Akt pathway and its effect on glial cell line-derived neurotrophic factor in midbrain dopamine cells

  2007cites this paper
• Adult neural stem and progenitor cells modified to secrete GDNF can protect, migrate and integrate after intracerebral transplantation in rats with transient forebrain ischemia

  2007cites this paper
• Neurotrophic factors for the treatment of Parkinson's disease.

  2007cites this paper
• The influence of the foreign body response evoked by fibroblast transplantation on soluble factor diffusion in surrounding brain tissue.

  2007cites this paper
• Glial cell line-derived neurotrophic factor (GDNF) therapy for Parkinson's disease.

  2007cites this paper
• [Neurological disorders and neural regeneration: special reference to Parkinson's disease and cerebral ischemia].

  2007cites this paper
• Intracerebral Transplantation of Genetically Engineered Cells for Parkinson's Disease: Toward Clinical Application

  2007cites this paper
• The future of cell therapies in the treatment of Parkinson's disease

  2007cites this paper
• Controlled Secretion of β-endorphin from Human Embryonic Kidney Cells Carrying a Tet-on-NL1-β-endorphin Fusion Gene: Gene Therapy of Pain

  2006cites this paper
• Ex vivo gene therapy: transplantation of neurotrophic factor-secreting cells for cerebral ischemia.

  2006cites this paper
• Therapeutic modulation of growth factors and cytokines in regenerative medicine.

  2006cites this paper
• Continuous exposure to glial cell line-derived neurotrophic factor to mature dopaminergic transplants impairs the graft's ability to improve spontaneous motor behavior in parkinsonian rats.

  2006cites this paper
• Gene Therapy Applications for Parkinson’s Disease

  2006cites this paper
• COLABORACIÓN ESPECIAL Terapias neuroprotectoras y neurorestauradoras en el tratamiento de la enfermedad de Parkinson Neuroprotective and neurorestorative therapies for the treatment of Parkinson's disease

  2006cites this paper
• [Neuroprotective and neurorestorative therapies for the treatment of Parkinson's disease].

  2006cites this paper
• Intravenous administration of glial cell line‐derived neurotrophic factor gene‐modified human mesenchymal stem cells protects against injury in a cerebral ischemia model in the adult rat

  2006cites this paper
• Genetically Modified Cell Line Grafting for the Treatment of Parkinson’s Disease

  2006cites this paper
• Encapsulated vascular endothelial growth factor-secreting cell grafts have neuroprotective and angiogenic effects on focal cerebral ischemia.

  2005cites this paper
• New Therapeutic Approaches to Parkinson’s Disease Including Neural Transplants

  2005cites this paper
• Neurorescue effects of VEGF on a rat model of Parkinson's disease.

  2005cites this paper
• Delayed gene therapy of glial cell line-derived neurotrophic factor is efficacious in a rat model of Parkinson's disease.

  2005cites this paper
• Microcapsules prepared with different biomaterials to immobilize GDNF secreting 3T3 fibroblasts.

  2005cites this paper
• Mesenchymal stem cells that produce neurotrophic factors reduce ischemic damage in the rat middle cerebral artery occlusion model.

  2005cites this paper
• Early transplantation of an encapsulated glial cell line-derived neurotrophic factor-producing cell demonstrating strong neuroprotective effects in a rat model of Parkinson disease.

  2005cites this paper
• Cell therapy for inner ear diseases.

  2005cites this paper
• The differences between high and low-dose administration of VEGF to dopaminergic neurons of in vitro and in vivo Parkinson's disease model.

  2005cites this paper
• Neuroprotective effects of vascular endothelial growth factor (VEGF) upon dopaminergic neurons in a rat model of Parkinson's disease

  2004cites this paper
• N. Pavón-Fuentes, L. Blanco-Lezcano, L. Martínez-Martín, L. Castillo-Díaz, K. de la Cuétara-Bernal, R. García-Miniet, L. Lorigados-Pedre, Y. Coro-Grave de Peralta, A. García-Varona, J.C. Rosillo-Martí, R. Macías-González

  2004cites this paper
• Gene therapy in Parkinson’s disease

  2004cites this paper
• [Stromal cell transplant in the 6-OHDA lesion model].

  2004cites this paper
• Cell-based therapies for Parkinson's disease

  2004cites this paper
• Application of cell therapy to inner ear diseases.

  2004cites this paper
• Controlled secretion of beta-endorphin from human embryonic kidney cells carrying a Tet-on-beta-endorphin fusion gene.

  2004cites this paper
• Parkinson's disease from a viewpoint of regenerative medicine

  2004cites this paper
• Monitoring cell therapy using iron oxide MR contrast agents.

  2004cites this paper
• Controlled secretion of β-endorphin from human embryonic kidney cells carrying a Tet-on-β-endorphin fusion gene

  2004cites this paper
• Intraparenchymal delivery of GDNF towards a treatment for Parkinson ’ s disease Review Article

  2004cites this paper
• Olfactory ensheathing cell transplantation restores functional deficits in rat model of Parkinson's disease: a cotransplantation approach with fetal ventral mesencephalic cells.

  2004cites this paper
• The Potential Role of Vascular Endothelial Growth Factor in the Central Nervous System

  2004cites this paper
• Implantation of encapsulated glial cell line-derived neurotrophic factor-secreting cells prevents long-lasting learning impairment following neonatal hypoxic-ischemic brain insult in rats.

  2004cites this paper
• Encapsulated GDNF-producing C2C12 cells for Parkinson's disease: a pre-clinical study in chronic MPTP-treated baboons.

  2004cites this paper
• The potential of GDNF as a treatment for Parkinson's disease.

  2004cites this paper
• Stereotactic transplantation of a dopamine-producing capsule into the striatum for treatment of Parkinson disease: a preclinical primate study.

  2003cites this paper
• Gene therapy progress and prospects: Parkinson's disease

  2003cites this paper
• Cell therapy for cerebral ischemia using vascular endothelial growth factor-secreting cells

  2003cites this paper
• Making connections: the development of mesencephalic dopaminergic neurons.

  2003cites this paper
• Long term gene therapy of Parkinson's disease using immortalized rat glial cell line with tyrosine hydroxylase gene.

  2003cites this paper
• Neurotrophic factor delivery by encapsulated cell grafts

  2003cites this paper
• Grafting of glial cell line-derived neurotrophic factor secreting cells for hypoxic-ischemic encephalopathy in neonatal rats.

  2003cites this paper
• Complications of a trophic xenotransplant approach in parkinsonian monkeys.

  2003cites this paper